Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity

Blocking the programmed death-ligand 1 (PD-L1) on tumor cells with monoclonal antibody therapy has emerged as powerful weapon in cancer immunotherapy. However, only a minority of patients presented immune responses in clinical trials. To develop an alternative treatment method based on immune checkp...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Huan, Tan, Songwei, Gao, Xueqin, Zou, Chenming, Xu, Chenfeng, Tu, Kun, Song, Qingle, Fan, Fengjuan, Huang, Wei, Zhang, Zhiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016277/
https://www.ncbi.nlm.nih.gov/pubmed/32082979
http://dx.doi.org/10.1016/j.apsb.2019.07.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016277/
https://www.ncbi.nlm.nih.gov/pubmed/32082979
http://dx.doi.org/10.1016/j.apsb.2019.07.004

Ejemplares similares